Amicus Therapeutics is successfully transitioning toward a self-sustaining commercial model, evidenced by 23.7% year-over-year revenue growth in 2025Q4 and a shift to positive operating income of $15.9 million. While the Pompe disease franchise provides a clea...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Feb 20, 2026 | $0.01-86.0% vs $0.07 | $185M+2.6% vs $181M |
Q4 2025 Nov 4, 2025 | $0.06+55.6% vs $0.04 | $169M+2.0% vs $166M |
Q3 2025 Jul 31, 2025 | -$0.08-60.0% vs -$0.05 | $155M+5.5% vs $147M |
Q2 2025 May 1, 2025 | -$0.07-800.0% vs $0.01 | $125M-7.8% vs $136M |
Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.
Benchmark FOLD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amicus Therapeutics, Inc. (FOLD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -11.58% | — | |
| $15.62 | $1.54B | -2.68 | 20.13% | -81.79% | — | — | |
| $20.81 | $2.2B | -2.92 | 15.58% | -6.93% | -9.96% | — | |
| $63.37 | $12.25B | 35.21 | 12.87% | 2.14% | 1.18% | — | |
| $45.75 | $7.6B | -19.22 | 33.87% | -64.64% | -110.84% | — | |
| $350.88 | $10.34B | 51.30 | 33.94% | 54.82% | 19.34% | — |
Amicus Therapeutics, Inc. (FOLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Amicus Therapeutics, Inc. (FOLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 27, 2026·SEC
Apr 23, 2026·SEC
Mar 3, 2026·SEC
Get notified when FOLD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amicus Therapeutics, Inc. (FOLD) stock FAQ — growth, dividends, profitability & financials explained
Amicus Therapeutics, Inc. (FOLD) reported $634.2M in revenue for fiscal year 2025.
Amicus Therapeutics, Inc. (FOLD) grew revenue by 20.0% over the past year. This is strong growth.
Amicus Therapeutics, Inc. (FOLD) reported a net loss of $27.1M for fiscal year 2025.
Amicus Therapeutics, Inc. (FOLD) has a return on equity (ROE) of -11.6%. Negative ROE indicates the company is unprofitable.
Amicus Therapeutics, Inc. (FOLD) generated $29.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
